Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Treatment of Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) by Hormone Shock and Sirolimus Maintenance

NCT04409691 is registered in ClinicalTrials.gov with Shanghai Children's Medical Center as lead sponsor.

NCT NCT04409691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04409691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Treatment of Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) by Hormone Shock and Sirolimus Maintenance
Lead sponsor
Shanghai Children's Medical Center
Phase
Phase 1
Overall status
Unknown status
Start date
July 1, 2020
Completion date
June 30, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kaposiform hemangioendothelioma (khe) with kasabach-merritt phenomenon (kmp)